Navigation Links
New Drug Combo for Hepatitis C Shows Promise
Date:1/19/2012

By Mary Brophy Marcus
HealthDay Reporter

WEDNESDAY, Jan. 18 (HealthDay News) -- A new cocktail of two investigational drugs appears to have successfully cleared the hepatitis C virus in people who don't respond to standard treatment.

What's more, the approach seems to work without the need for injections with interferon alpha, an onerous medication that causes serious side effects in many patients.

Scientists from seven U.S. medical centers and drug maker Bristol-Myers Squibb published the small study in the Jan. 19 issue of the New England Journal of Medicine that is being heralded as "landmark" research.

"We saw a sustained virologic response -- the virus was undetectable in the patients -- during treatment and remained undetectable after the drugs were stopped," said study author Dr. Anna Lok, director of clinical hepatology at the University of Michigan Medical School in Ann Arbor.

Hepatitis C virus, spread through contact with contaminated blood, is the most common form of the virus and affects 180 million people globally, including 4.1 million Americans. It's the leading cause of chronic liver disease, and can lead to liver cancer. The standard treatment includes injections of the antiviral drug interferon alpha, which isn't tolerated well by everyone, said Dr. Andrew Muir, director of gastroenterology and hepatology research at the Duke Clinical Research Institute. Its many side effects include flu-like symptoms, fatigue, fever and depression.

"Many patients cannot complete treatment or decide not to take treatment because of interferon alpha," Muir said.

The study had two arms, said Lok. A group of 10 patients received four medications, including the two investigational drugs, the antivirals daclatasvir and asunaprevir, along with the standard treatment combination of interferon and ribavirin. The other arm of the study included 11 patients who received only the two investigational drugs. Both groups underwent treatment for 24 weeks.

The 10 patients on the four-drug regimen experienced a sustained virologic response with undetectable virus at the end of treatment and again at 12 weeks beyond their treatment, the researchers reported. In the two-drug group, four of the 11 patients also had undetectable levels of the hepatitis C virus in their blood 12 weeks after treatment ended.

All of the patients were infected with genotype 1, the most common type of hepatitis C virus in the United States, and had not responded to previous treatment with interferon and ribavirin, said Lok.

"The four-drug arm was very impressive. These patients had not shown a response before and now we get a 90 to 100 percent rate of sustained response," said Lok.

She said even though only four patients in the two-drug group reached a sustained response, this is the first study to show it can be achieved without interferon or ribavirin.

"Clearly, this is the biggest development in hepatitis C research in a very long time," said Dr. Raymond Chung, director of hepatology at Massachusetts General Hospital in Boston, who wrote an accompanying editorial in the same issue of the journal. "It has enormous implications for our ability to treat many more patients with regimens that are significantly more tolerable."

The most common side effects reported were headache, diarrhea, nausea and fatigue, the study authors said.

Chung called the study "a watershed moment" because it suggests that an interferon-free treatment is possible. "The conventional wisdom for quite some time has been that hepatitis C would likely not be curable without an interferon backbone."

Duke's Dr. Muir added, "The study is also exceptional because it included patients we would describe as the most difficult to treat." Their viral load did not go down very much when they underwent interferon and ribavirin treatment in the past.

The new drugs are not FDA-approved yet, but a number of trials are under way, said Chung, who believes an interferon-sparing regimen is only a few years away. "It is not beyond belief that we'll have an all-oral therapy available as early as 2015. That's the pace it's going right now," he said.

"There's certainly hope," said Lok, who noted that the research was funded by drug maker Bristol-Myers Squibb.

More information

The U.S. National Institutes of Health has more on clinical trials for hepatitis C.

SOURCES: Anna Lok, M.D., director, clinical hepatology, University of Michigan Medical School, Ann Arbor; Andrew Muir, M.D., director, gastroenterology and hepatology research, Duke Clinical Research Institute, Durham, N.C.; Raymond Chung, M.D., chief, hepatology, Massachusetts General Hospital, Boston; Jan. 19, 2012, New England Journal of Medicine


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Short-Term Drug Combo May Help Prevent Colon Cancer
2. Bone Marrow Cancer Patients May Benefit From Drug Combo
3. Drug Combo Staves Off Type 2 Diabetes
4. Binge Drinking, Hypertension a Deadly Combo
5. Exercise Combo Best for Type 2 Diabetes
6. New combo lung cancer therapy improves survival over single-line treatment
7. In Women, Diabetes Plus Depression a Deadly Combo
8. Risks May Outweigh Benefits for Blood Pressure Drug Combo
9. Diet-Exercise Combo Seems to Work Best for Obese Seniors
10. Low-Intensity Exercise, Drug Combo Can Help Parkinsons Patients, Studies Show
11. Alcohol-Energy Drink Combo Riskier Than Booze Alone, Study Says
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
New Drug Combo for Hepatitis C Shows Promise
(Date:6/23/2017)... Providence, RI (PRWEB) , ... June 23, 2017 ... ... Community Care Network today announced the launch of Care Management Alerts and Dashboards, ... for 140,000 patients throughout Rhode Island. , RIQI’s Care Management Alerts and Dashboards ...
(Date:6/23/2017)... ... June 23, 2017 , ... The Military Officers Association of America (MOAA) ... of Veterans Affairs, retired Marine Col. Thomas G. Bowman. , Bowman currently serves as ... brings an intimacy with the issues and challenges veterans face with the VA. Following ...
(Date:6/23/2017)... ... June 23, 2017 , ... The Aesthetic Channel has recently highlighted ... has come up with a proprietary technique that he calls the AuraLyft ... dropped. For all ages, patients can expect to look refreshed, rejuvenated, and revitalized. ...
(Date:6/23/2017)... ... 23, 2017 , ... PureLife Dental is pleased to announce that California Dental ... As part of the amalgam separator endorsement, all CDA members may purchase an ECO ... the retail value. This partnership between PureLife and CDA is especially timely as it ...
(Date:6/23/2017)... ... June 23, 2017 , ... Jusino ... services to communities in the greater Chicago metropolitan area, is embarking on a ... underprivileged youth in Chicago. , Founded in 1897, Hephzibah Children’s Association is one ...
Breaking Medicine News(10 mins):
(Date:6/14/2017)... 14, 2017 The Bio Supply Management Alliance ... of Fremont and the Biomedical Manufacturing Network ... in California by providing a ... and fostering workforce development. The primary focus of this ... start-ups, as well as small and mid-sized biomedical companies. ...
(Date:6/12/2017)... 12, 2017 Kineta, Inc., a biotechnology company focused ... Vice President of R&D and Head of Virology Kristin ... Preparedness for the Northwest and Beyond meeting sponsored by ... 14, 2017 from 8:30-10:30 AM PDT at the Agora Conference ... Dr. Bedard will be joined by other leaders in ...
(Date:6/9/2017)... PALO ALTO, Calif. , June 9, 2017 /PRNewswire/ ... medical device company focused on the design, manufacture, sale ... updated the market on the progress of its commercial ... AeroForm is now available in more than one hundred ... country. AeroForm offers a needle-free alternative ...
Breaking Medicine Technology: